Funding
← Back to your selection

Janus Henderson Investors

Activity from announced rounds

Activity in this selectionHealthtech

Janus Henderson Investors is an asset manager with specialist healthcare investing capabilities, including a biotechnology strategy that invests in both public and private companies.

Its Biotechnology Innovation strategy uses long-term, research-intensive analysis across the biotech landscape. The healthcare team evaluates businesses addressing unmet medical needs and technologies intended to improve the efficiency and cost of care.

The biotechnology strategy combines long investments with short selling in its portfolio construction. Private-company investment is part of this specialist asset-management activity, alongside the firm’s broader range of investment strategies.

Sources
Rounds participated in
4
Confirmed lead rounds
0
3 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$360M
4 disclosed · full round size, not this investor’s share

By stage

Series A2
Series B1
Series C+1

By primary sector

Biotech3
Healthtech1

By country

United States4

Rounds

4 in this selection
Calyxo

Develops medical devices for kidney stone treatment and removal

$40MSeries F
Role not disclosed
Ambrosia Biosciences

Drug-discovery company developing oral small-molecule treatments for obesity and metabolic disorders.

$100MSeries B
Participant
Poplar Therapeutics

Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions

$45MSeries A+
Role not disclosed